Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $27.5052W HIGH $40.71
Volume
177.89 K
Value Traded
10.24 M
Short % Float
15.5%
Days to Cover
20.7
+3.82%Week
+1.11%1 Month
-8.26%3 Month
+8.47%6 Month
-22.35%5 Year
-29.68%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.60 B
EPS (TTM)
-0.35
P/E Ratio
-
Ent. Value
715.22 M
Total Shares
51.50 M
Float Shares
51.00 M
Insiders
0.96%
Institutions
95.61%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
IMCR Catalyst Timeline
Dated clinical, regulatory and corporate events for Immunocore Holdings plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immunocore Holdings plc
496Total events
15Upcoming
92Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Trial InitiationIMC-S118AITrial
Phase 1 dose escalation trial of IMC-S118AI in HLA-A*02:01-positive type 1 diabetes patients
type 1 diabetessource ↗
▲First Patient DosedIMC-S118AITrial
First patient with type 1 diabetes dosed in Phase 1 trial of IMC-S118AI
type 1 diabetessource ↗
▲Enrollment CompleteKIMMTRAKApprovedTrial
Target enrollment (540 patients) achieved in registrational Phase 3 TEBE-AM trial
previously treated advanced melanomasource ↗
●Enrollment UpdateTebentafuspApprovedTrial
TEBE-AM enrollment nearing target of 540 patients
previously treated advanced cutaneous melanomasource ↗
▲Enrollment CompleteIMC-M113VTrial
Enrollment completed for higher dose cohorts of IMC-M113V
HIVsource ↗
●Enrollment UpdateBrenetafuspTrial
PRISM-MEL-301 randomization ongoing
first-line advanced cutaneous melanomasource ↗
▲First Patient DosedIMC-S118AITrial
First type 1 diabetes patient dosing expected in coming weeks
type 1 diabetessource ↗
●Enrollment UpdateIMC-P115CTrial
IMC-P115C Phase 1 dose escalation enrolling patients
multiple solid tumorssource ↗
▲Product LaunchKIMMTRAKApprovedPost-Market
KIMMTRAK launched in over 30 countries
metastatic uveal melanomasource ↗
●Enrollment UpdateIMC-M113VTrial
IMC-M113V enrollment completed at higher dose cohorts up to 1200 mcg
HIVsource ↗
◆Trial InitiationIMC-S118AITrial
First type 1 diabetes patient to be dosed in coming weeks
type 1 diabetessource ↗
▲First Patient DosedIMC-S118AITrial
First type 1 diabetes patient expected to be dosed in coming weeks
type 1 diabetessource ↗
▲Oral PresentationIMC-M113VPresentation
Translational data presented at IAS meeting in July 2026
HIVsource ↗
▲Quarterly UpdateKIMMTRAKApprovedCorporate
KIMMTRAK Q2 2026 net revenues of $115.9 million
metastatic uveal melanomasource ↗
◆Poster PresentationBrenetafuspPresentation
Updated Phase 1 data of brenetafusp in heavily pretreated advanced melanoma presented at ASCO 2026
advanced melanomasource ↗
◆Trial InitiationBrenetafuspTrial
Phase 3 PRISM-MEL-301 trial ongoing with brenetafusp + nivolumab vs standard nivolumab regimens
first-line advanced melanomasource ↗
◆Poster PresentationPresentation
Effect of IL7 on T cell fitness and ImmTAC anti-tumor activity presented at ASCO 2026
cancersource ↗
◆Oral PresentationKIMMTRAKApprovedPresentation
Five-year overall survival data for KIMMTRAK at AACR 2026
unresected or metastatic uveal melanomasource ↗
◆Oral PresentationPresentation
Immunocore management to present at 25th Annual Needham Virtual Healthcare Conference
▲Oral PresentationKIMMTRAKApprovedPresentation
Five-year overall survival data from Phase 3 trial of KIMMTRAK presented at AACR 2026
metastatic uveal melanomasource ↗
▲PublicationIMC-S118AIPresentation
Preclinical data for IMC-S118AI published in Science Advances
type 1 diabetessource ↗
●Oral PresentationPresentation
Jefferies 2026 Biotech on the Beach Summit 1x1s and small group meetings
●Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference 1x1s and small group meetings
◆Quarterly UpdateCorporate
Report final Q4 and full-year 2025 financial results in late February 2026
▲Management ChangeCorporate
Dr. Mohammed Dar promoted to EVP, expanded oversight of clinical development
◆Oral PresentationPresentation
Company to present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
▲Enrollment CompleteTebentafuspApprovedTrial
Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026
second-line or later advanced cutaneous melanomasource ↗
◆Enrollment CompleteTebentafuspApprovedTrial
TEBE-AM enrollment completion anticipated 1H 2026
advanced cutaneous melanomasource ↗
◆Trial InitiationTrial
First autoimmune candidate expected to enter clinic in 1H 2026
autoimmune diseasesource ↗
◆First Patient DosedTrial
Planning to dose first patient in Phase 1 type 1 diabetes trial in 1H 2026
type 1 diabetessource ↗
◆Enrollment CompleteKIMMTRAKApprovedTrial
Expect to complete enrollment in TEBE-AM trial in 1H 2026
previously treated cutaneous melanomasource ↗
▲Oral PresentationKIMMTRAKApprovedPresentation
Five-year OS data presented at AACR 2026
metastatic uveal melanomasource ↗
▲Oral PresentationBrenetafuspPresentation
Phase 1/2 brenetafusp data presented at ASCO 2026
advanced melanomasource ↗
◆Oral PresentationPresentation
Guggenheim 2nd Annual Healthcare Innovation Conference Fireside Chat
◆Poster PresentationIMC-I109VPresentation
Poster presentation of Phase 1 single ascending dose data for IMC-I109V at AASLD The Liver Meeting
chronic hepatitis Bsource ↗
▲Dose Finding UpdateBrenetafuspTrial
160 mcg selected as go-forward dose for brenetafusp in PRISM-MEL-301 following IDMC review
first-line advanced cutaneous melanomasource ↗
◆Oral PresentationPresentation
Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat
Past FDA Catalysts and PDUFA Decisions
How IMCR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | IMC-S118AI | IND Submission | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 9%
Micro Cap(rank 60 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| KIMMTRAK |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Brenetafusp Small moleculeNCT06112314 | Advanced Melanoma | Phase 3 | RECRUITING | 680 | Oct 16, 2027 | ||||||
| Brenetafusp Small moleculeNCT04262466 | Select Advanced Solid Tumors | Phase 1 | ACTIVE NOT_RECRUITING | 410 | Dec 1, 2027 | ||||||
| IMC-P115C Small moleculeNCT07156136 | PRAME Positive | Phase 1 | RECRUITING | 140 | Aug 30, 2029 | ||||||
| IMC-S118AI Monoclonal antibodyNCT07493122 | Type 1 Diabetes | Phase 1 | NOT YET_RECRUITING | 154 | Nov 1, 2030 | ||||||
| IMC-R117C Small moleculeNCT06840119 | Cancer | Phase 1 | RECRUITING | 600 | Nov 30, 2027 | ||||||
| Tebentafusp Small moleculeMarketedNCT06070012 | Uveal Melanoma | Phase 3 | RECRUITING | 334 | Sep 30, 2030 | ||||||
| Tebentafusp Small moleculeMarketedNCT05549297 | Advanced Melanoma | Phase 3 | RECRUITING | 540 | Jul 1, 2028 | ||||||
| Tebentafusp Small moleculeMarketedNCT05315258 | Melanoma (Skin) | Phase 2 | ACTIVE NOT_RECRUITING | 850 | Jun 30, 2027 | ||||||
| Tebentafusp Small moleculeMarketedNCT06627244 | Metastatic Uveal Melanoma | Phase 2 | RECRUITING | 30 | Feb 17, 2031 | ||||||
| IMCgp100 Small moleculeMarketedNCT02570308 | Uveal Melanoma | Phase 2 | COMPLETED | 524 | Oct 17, 2022 | ||||||
| IMCgp100 Small moleculeMarketedNCT01211262 | Malignant Melanoma | Phase 1 | COMPLETED | 84 | Feb 16, 2017 |
Clinical Trial Results
Readouts, endpoints and source filings for every IMCR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| brenetafusp | heavily pretreated advanced melanoma | Phase 1/2 | 2026-05-31 | overall survival rate 6 months: 87%; disease control rate: 52%; median overall survival: 14.3 months; overall response rate: 12%; median overall survival primary PD1 resistance: 14.7 months; ct DNA response primary PD1 resistance: 53%; ct DNA response overall group: 38%Read More | Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanomaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ratcliffe Peter JohnDirector | Grant/Award | 27,492 27,492 held | $0.00 | 05/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IMCR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 1.3 % (-13.3 %) | 154.62 M | 4.87 M |
IMCR Institutional Ownership Trends
IMCR Short Interest
Shares sold short, counted twice a month.
15.5%
Short % of Float
of tradable shares sold short
7.9M
Shares Sold Short
+1.7% vs prior count
20.7 Very high
Days to Cover
trading days of normal volume to buy every short share back
381.7K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IMCR ranks across every disease it competes in
Competitive Position is a premium feature
See how IMCR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIMCR News
IMCRImmunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
Immunocore has initiated a Phase 1 trial for IMC-S118AI, its first tissue-specific autoimmune candidate targeting type 1 diabetes. The trial aims to evaluate the safety and clinical activity of this bispecific molecule in HLA-A*02:01-positive patients. Preclinical studies have shown promising results in protecting beta cells from T cell attacks, indicating potential for effective treatment.
Read more →IMCRImmunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Immunocore has successfully achieved target enrollment of 540 patients in the TEBE-AM trial, evaluating KIMMTRAK for advanced melanoma. The trial aims to assess overall survival in patients who have progressed after prior therapies. Topline results are anticipated by the end of 2026, addressing an unmet need in this patient population.
Read more →IMCRImmunocore to present at upcoming investor conferences
Immunocore Holdings plc announced its participation in several upcoming investor conferences in September 2026. The conferences include the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. Presentations will be webcast live and available for replay on Immunocore's website.
Read more →IMCRImmunocore reports second quarter financial results and provides a business update
Immunocore reported a strong second quarter for 2026, with KIMMTRAK generating $115.9 million in net revenues, an 18% increase from the previous year. The company is nearing completion of patient enrollment in its Phase 3 TEBE-AM trial for advanced cutaneous melanoma. Additionally, promising five-year survival data for KIMMTRAK was presented, highlighting its effectiveness in treating metastatic uveal melanoma.
Read more →IMCRImmunocore to report second quarter 2026 financial results and host call on August 6, 2026
Immunocore Holdings plc will report its second quarter 2026 financial results on August 6, 2026. Following the announcement, a live teleconference will be held to discuss the results and provide a business update. The company is known for its innovative TCR bispecific immunotherapies, particularly KIMMTRAK, which has received approvals in several regions.
Read more →IMCRImmunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore has presented updated Phase 1 data for brenetafusp, showing an 87% overall survival rate at 6 months in heavily pretreated advanced melanoma patients. The data supports the selection of a 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial. Brenetafusp demonstrated consistent clinical benefits across difficult-to-treat subgroups, including those with primary PD-1 resistance.
Read more →IMCR▲ +6.6%on this news
Immunocore reports first quarter financial results and provides a business update
Immunocore reported a strong financial performance for Q1 2026, with KIMMTRAK generating $106.7 million in net sales, a 14% increase from the previous year. The company highlighted significant survival data from a Phase 3 trial presented at AACR, marking a pivotal moment for KIMMTRAK in treating metastatic uveal melanoma. Immunocore continues to expand its pipeline and market presence, with ongoing trials and a robust cash position.
Read more →IMCRKIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Immunocore Holdings announced that KIMMTRAK (tebentafusp-tebn) has doubled the five-year overall survival rate for HLA-A*02:01+ patients with metastatic uveal melanoma, achieving 16% compared to 8% in the control group. This represents the longest follow-up in a randomized trial for this condition. The results were presented at the AACR 2026 meeting, highlighting KIMMTRAK's potential as the first-line standard of care.
Read more →IMCRImmunocore to present at the 25th Annual Needham Virtual Healthcare Conference
Immunocore Holdings plc will present at the 25th Annual Needham Virtual Healthcare Conference, which is scheduled for April 13, 2026. The company, known for its innovative immunomodulating medicines, is leveraging its ImmTAX platform to develop treatments targeting cancer, autoimmune diseases, and infectious diseases. Attendees can access the live webcast of the presentation on Immunocore's website, which will also host a replay afterward.
Read more →IMCRImmunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Immunocore Holdings plc announced that it will present five-year overall survival data for KIMMTRAK at the 2026 AACR Annual Meeting. This data, derived from a Phase 3 trial in patients with metastatic uveal melanoma, represents the longest follow-up in a randomized trial for this condition. The presentation will also include additional data on subsequent treatments and prognostic factors.
Read more →IMCRImmunocore reports fourth quarter and full year 2025 financial results and provides a business update
Immunocore reported strong financial results for Q4 and full year 2025, with KIMMTRAK generating $400 million in sales. The company anticipates completing enrollment for TEBE-AM in 1H 2026 and presenting Phase 1/2 data for its PRAME franchise in 2H 2026. Despite the positive growth, revenue moderation is expected in 2026.
Read more →IMCRImmunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
Immunocore Holdings plc will report its fourth quarter and full year 2025 financial results on February 25, 2026. Following the announcement, a live teleconference will be held to discuss the results and provide updates on the company's business and portfolio. Immunocore is known for its innovative TCR bispecific immunotherapies, including the approved KIMMTRAK for certain cancer patients.
Read more →IMCRImmunocore announces R&D leadership evolution
Immunocore Holdings plc announced the departure of Dr. David Berman, Executive Vice President of R&D, effective February 27, 2026. In his place, Dr. Mohammed Dar and Mark Moyer have been promoted to Executive Vice President roles, enhancing their oversight of clinical development and regulatory strategies. The company aims to streamline its R&D structure while maintaining its focus on ongoing clinical programs.
Read more →IMCRImmunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
Immunocore has outlined its strategic priorities for 2026 at the J.P. Morgan Healthcare Conference, focusing on expanding its melanoma franchise with KIMMTRAK and enrolling in three Phase 3 trials. The company anticipates presenting Phase 1/2 data for its PRAME franchise and initiating a Phase 1 trial for type 1 diabetes. With a strong cash position, Immunocore aims to address high unmet needs in oncology and autoimmune diseases.
Read more →IMCR▲ +6%on this newsshared move
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
Immunocore presented Phase 1 trial data for IMC-I109V, a bispecific T cell receptor targeting hepatitis B. The trial demonstrated a manageable safety profile and antiviral activity, with dose-dependent reductions in HBsAg levels. The findings support further investigation of this novel therapy for chronic HBV infection.
Read more →IMCRImmunocore reports third quarter financial results and provides a business update
Immunocore reported a strong third quarter for 2025, with KIMMTRAK net revenues reaching $103.7 million, a 29% increase year-over-year. The company is on track with its Phase 3 trials, including the TEBE-AM trial, expected to complete enrollment in the first half of 2026. Despite a net loss this quarter, Immunocore maintains a robust cash position of $892 million.
Read more →About Immunocore Holdings plc
Headquarters90 PARK DRIVE, OXFORDSHIRE, X0, OX14 4RY
BIOPHARMAWATCH ELITE PLUS
Trade the next IMCR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime